• Pure Extracts Technologies Corp. (PULL) has submitted a licence application to Health Canada for a new blended functional mushroom wellness product
  • The new product provides antioxidants that help protect cells against the oxidative damage caused by free radicals
  • The blended formula is expected to launch in the fourth quarter of 2021
  • Pure Extracts Technologies is a plant-based extraction company
  • Pure Extracts Technologies Corp. (PULL) is up 2.44 per cent, trading at $0.42 per share

Pure Extracts Technologies Corp. (PULL) has submitted a licence application to Health Canada for a new blended functional mushroom wellness product.

Ben Nikolaevsky, Pure Extracts CEO, commented on the company’s recent progress.

“We are excited to be creating our next Pure Mushrooms products for our direct-to-consumer, online store,” he said. “As we build-out our mushroom extraction facility, we plan to bring more products to market.”

The application is for a blend of cordyceps, reishi, and lion’s mane mushrooms, following up on the company’s Amazon launch of its reishi and maitake formulations.

The new blended formula provides antioxidants that help protect cells against the oxidative damage caused by free radicals.

“The functional mushroom wellness market is experiencing robust sales,” added Mr. Nikolaevsky, “as many consumers are trying to boost their immune systems in light of the COVID-19 pandemic.”

The reishi and maitake formulations sold on the company’s Amazon e-commerce store have proven to be appealing to both men and women, with the most sales in California, Florida, and Georgia.

The blended formula is expected to launch in the fourth quarter of 2021, pending approval from Health Canada’s Natural and Non-Prescription Health Products Directorate.

Pure Extracts Technologies is a plant-based extraction company that specializes in the processing of cannabis, hemp and functional mushrooms.

The company’s new, state-of-the-art processing facility is located just 20 minutes north of Whistler, British Columbia.

Pure Extracts Technologies Corp. (PULL) is up 2.44 per cent, trading at $0.42 per share as of 2:24 pm ET.

More From The Market Online
Psychedelic pills

Canadian psychedelic stock to supply MDMA to Yale

Canadian psychedelic stock PharmAla Biotech (CSE:MDMA) is up after signing a contract to supply MDMA for a clinical trial at Yale University.
MindBio Therapeutics chief executive officer Justin Hanka.

MindBio advances world-first psychedelic microdosing clinical trials

MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
Psilocybin mushrooms

Optimi will test its psilocybin on frontline healthcare workers

Health Canada clears psychedelics stock Optimi Health (CSE:OPTI) to test its psilocybin on frontline healthcare workers.
A hand holding blocks that spells out PTSD

Optimi Health ships first MDMA capsules to Australia to treat PTSD

Optimi Health (CSE:OPTI) reveals it has completed the inaugural export of its GMP-validated MDMA capsules to Australia.